All India Institute of Medical Sciences Raipur (AIIMS Raipur) is a medical college and medical research public university located in Raipur, Chhattisgarh, India.It is one of the six AIIMS healthcare established in 2012, and it operates autonomously under the Ministry of Home Affairs (India), Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY).
PURPOSE: Aberrant Internal carotid artery (ICA) within the middle ear is a rare congenital vascular anomaly, occurring in approximately 1% of the population [1]. It often remains clinically silent or presents with nonspecific otological symptoms, making preoperative diagnosis challenging. This study aims to highlight the importance of early identification and safe management of aberrant ICA through a clinical case and literature review. METHODS: We report a case of 36 year old female presenting with bilateral chronic ear discharge and tympanic membrane retraction. Detailed otoscopic examination and radiological imaging were performed. A focused literature review was conducted to contextualize clinical presentation, diagnostic strategies and management. RESULTS: Imaging revealed an aberrant ICA coursing through the middle ear. The patients presentation was non specific, and the diagnosis was established only after radiological evaluation. Recognition of this anomaly preoperatively prevented inadvertent vascular injury. Literature suggests that such cases are frequently diagnosed incidentally, with intraoperative hemorrhage being the most severe complication when missed. CONCLUSION: Preoperative identification of aberrant ICA is critical in patients with atypical middle ear findings. Routine consideration of vascular anomalies and appropriate imaging can avert life threatening complications and guide safe surgical planning.
The magnitude of the problem of sickle cell disease (SCD) in India is very large and diverse. For people living with SCD there are several unmet health care needs making it pertinent to focus on recognizing the important public health burden of SCD in the country. In a bid to achieve this goal, the Indian College of Hematology (ICH) of the Indian Society of Hematology and Blood Transfusion (ISHBT) in collaboration with Indian Council of Medical Research (ICMR) has formulated a Guideline on Management and Control of Sickle Cell Disease in India. This was achieved by a national taskforce comprising top experts from the field who held multiple sessions to deliberate on different aspects and form consensus on preparing a comprehensive document on SCD care in India. The taskforce has presented its recommendations on various aspects of SCD in India, all of which have been evaluated based on the best evidence. Where the evidence was weak, the recommendations have been based on consensus among the experts. This review which is adapted from the comprehensive guideline document gives a concise treatise on various aspects of sickle cell disease in India along with specific recommendations. The section on screening and diagnosis provides an evidence-based background to scientifically select the most appropriate and feasible test option(s) in various Indian practice settings. The other aspects covered in this review are management of SCD in stable condition, iron overload and chelation therapy, vaso-occlusive crisis, management of other complications of SCD, blood transfusion in SCD, haematopoietic stem cell transplant and gene therapy in SCD, immunization and antibiotic prophylaxis in SCD and monitoring of patients with SCD. It also gives guidance on special circumstances such as pregnancy and surgery in SCD. It concludes with a note on prevention and control of SCD in India with an outline of a defined roadmap to make this possible.
Fibronectin (FN1), a vital extracellular matrix protein, has been reported to be elevated in blood and cerebrospinal fluid in epileptic patients exhibiting recent seizure activity. A transcriptomic study from MTLE-HS patients has identified FN1 as a potential gene linked to MTLE. Nonetheless, the function of FN1 and the participation of the FN1/α5β1-Integrin/Src kinase signaling pathway are yet to be fully investigated in both pre-clinical and clinical investigations of TLE. Furthermore, its role in NMDA receptor-mediated hyperexcitability in TLE requires investigation. This study evaluates the contribution of the FN1/α5β1-Integrin/Src kinase axis in facilitating NMDA-induced hyperexcitability in temporal lobe epilepsy. Hippocampal formation and ATL tissues from MTLE-HS patients, as well as acute and chronic Li-pilocarpine TLE rat models, were examined using qRT-PCR, immunoblotting, and ex vivo immunolabeling to evaluate the expression of FN1, α5β1 Integrin, Src kinase, and NMDA receptor subunits. To assess the functions of FN1 and Src in NMDA receptor-induced hyperexcitability, siRNA-mediated knockdown was conducted in TLE rats. Following knockdown, behavioral assessments, molecular studies, and in vivo EEG were employed to examine the FN1/α5β1 Integrin/Src axis in seizure-related hyperexcitability.In MTLE-HS patients and TLE rat models, FN1 and Src kinase showed upregulation in both the hippocampal formation and ATL, together with increased α5β1 Integrin levels in rats. Elevated Src activity was associated with augmented phosphorylation of NMDA receptors. The siRNA-mediated knockdown of FN1 or Src diminished NMDA receptor phosphorylation and markedly reduced seizure activity in TLE animals. Our research suggests that FN1 has a role in MTLE pathophysiology and may regulate NMDAR-mediated hyperexcitability via the FN1/α5β1 Integrin/Src kinase pathway. This pathway regulates seizures via the hippocampal formation and anterior temporal lobe networks. The therapeutic potential of targeting this signaling pathway for epilepsy needs additional investigation.
Mucoepidermoid carcinoma (MEC) of the thyroid gland (TMEC) is exceptionally rare, with poorly understood histogenesis and molecular characteristics. This report describes a unique case of incidentally detected TMEC, accompanied by a comprehensive molecular characterization. A 60-year-old woman, during follow-up for diffuse large B-cell lymphoma, was detected to have a metabolically active lesion involving the thyroid gland. Resection revealed an infiltrative tumor composed of squamoid cells with focal gland formation and intracytoplasmic lumina. An adjoining focus of the infiltrative follicular subtype of papillary thyroid carcinoma (PTC) was also noted. Immunopositivity for CK19, p63, PAX8, and thyroglobulin and negativity for CD10 confirmed the diagnosis of mucoepidermoid carcinoma associated with PTC. MAML2 fusion was absent. Next-generation sequencing (NGS) revealed pathogenic/likely pathogenic variants involving genes previously documented in PTC. Post-recovery, the patient developed a third malignancy, squamous cell carcinoma involving the esophagus. The case has an unusual presentation, occurring in conjunction with two other metachronous malignancies. Co-existent PTC, immunopositivity for thyroid-differentiation markers, and the genetic profile confirm a squamoglandular metaplasia of follicular cells as the origin. The absence of MAML2 fusion questions its WHO categorization as a “salivary gland-type carcinoma.” Detailed molecular profiling, while contributing to a better understanding of the pathogenesis of this enigmatic neoplasm, also helped decipher potentially actionable genetic variants.
BACKGROUND:Appropriate tapering strategy for corticosteroids in ulcerative colitis (UC) is uncertain. AIM:To compare the efficacy and safety of two steroid tapering regimens in patients with active UC. METHODS:We randomised patients with active UC with initial steroid response after 2 weeks to short (total 6 weeks) or long taper (total 10 weeks). Randomization was stratified for acute severe UC. The primary outcome was steroid-free clinical remission at 6 months. Secondary outcomes included assessment of symptomatic remission, relapse rate, endoscopic and histological scores, and safety. RESULTS:Of 94 patients (48 in long, 46 in short taper) randomised, short taper was inferior to long taper in inducing clinical remission at 6 months (RR = 2.19; CI 1.08-4.46; p = 0.02). The relapse rates were similar in the long (37%) and short taper (46%) arms (HR: 0.34; CI: 0.10-1.11; p = 0.42). The median UCEIS scores (3 vs. 2; p = 0.23) and Nancy scores [2 (IQR 0-3) vs. 1.5 (0.75-3); p = 0.4] were not different between arms. Adverse events in the long and short taper arms, such as acne (14.58% vs. 2.16%), myopathy (8.33% vs. 6.52%), skin changes (2.08% vs. 2.17%), mood changes (0% vs. 4.34%), cytopenia (0% vs. 2.17%), and headache (6.25% vs. 6.52%) were similar. CONCLUSION:A shorter taper duration of 6 weeks was inferior to a longer taper of 10 weeks in achieving clinical remission of UC at 6 months. TRIAL REGISTRATION:CTRI Number: CTRI/2021/06/034129.